You are viewing a preview of...

AUP-55 - A Lactic Acid Bacterial Treatment for Ovarian Cancer, Bladder Cancer, and Peritoneal Carcinomatosis

Aurealis pre-clinical stage asset AUP-55 consists of genetically engineered lactic acid bacteria for the treatment of ovarian cancer, peritoneal carcinomatosis and bladder cancer. In ovarian cancer models in mice, treatment with AUP-55 resulted in 91.3 % survival and lower tumour load compared to 0 % survival and massively increased tumour load in untreated subjects.

Aurealis Therapeutics have provided the following sources to better demonstrate the capabilities of AUP-55:

  • Product Presentation
  • Relevant Publication (Journal of Clinical Oncology)

Log in or create a free account to continue reading